ArticleMolecular cancer therapeutics2020
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 59 citations in OpenAlex.
- Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.Proceedings of the National Academy of Sciences of the United States of America · 2026Trial
- Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.NPJ precision oncology · 2025Article
- All-trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin.Molecular cancer therapeutics · 2025Article
- Mitochondria-associated non-coding RNAs and their impact on drug resistance.Frontiers in pharmacology · 2025Review
- Advances in ovarian tumor stem cells and therapy.Cell biochemistry and biophysics · 2024Review
- Metastasis-enhancing protein KITENIN confers temozolomide resistance on glioblastoma with unmethylated MGMT via upregulation of cancer stem cell makers.Clinical and translational medicine · 2024Article
- Review
- Review
- Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.Cell communication and signaling : CCS · 2024Article
- Small molecule agents for triple negative breast cancer: Current status and future prospects.Translational oncology · 2024Review
- Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review.Oncology research · 2024Review
- PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.International journal of molecular sciences · 2023Article
- Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.iScience · 2023Article
- [SWI/SNF Complex Gene Mutations Promote the Liver Metastasis of Non-small Cell Lung Cancer Cells in NSI Mice].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression.NPJ precision oncology · 2023Article
- The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.International journal of molecular sciences · 2023Review
- Olaparib-ResistantCells · 2023Article
- Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.Journal of ovarian research · 2023Review
- PTTG1IP (PBF) is a prognostic marker and correlates with immune infiltrate in ovarian cancer.American journal of translational research · 2023Article
- Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma.Genes & cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 3 countries.
Lu Liu *Oncology Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Shurui Cai *Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Chunhua HanDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Ananya BanerjeeDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-9248-5778
Dayong WuDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Tiantian CuiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Guozhen XieDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Junran ZhangDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Xiaoli ZhangCenter for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio.
Eric McLaughlinCenter for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio.ORCID 0000-0003-2200-5905
Ming YinDivision of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio.
Floor J BackesDepartment of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-9225-6913
Arnab ChakravartiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio.
Yanfang ZhengOncology Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. qi-en.wang@osumc.edu 18665000236@163.com.
Qi-En WangDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio. qi-en.wang@osumc.edu 18665000236@163.com.
The Ohio State University · USZhujiang Hospital · CN
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MAverting recurrent and resistant ovarian tumorsR01CA211175 · NCI · OHIO STATE UNIVERSITY · PI WANG, QIEN · 2017 to 2021
$2.3MNCI NIH HHS P30 CA016058NCI NIH HHS R01 CA211175
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with
Indexed as
DNA RepairAldehyde Dehydrogenase 1 FamilyAnimalsAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinBromodomain Containing ProteinsCarcinoma, Ovarian EpithelialCell Cycle ProteinsCell Line, TumorDNA End-Joining RepairDrug Resistance, NeoplasmDrug SynergismFemaleHumansMiceAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsNCT-501Nuclear ProteinsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRetinal DehydrogenaseTheophyllineTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.